# HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

> **NCT00450580** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 212 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus I
- HIV-1 Infection

## Interventions

- **DRUG:** fosamprenavir/ritonavir

## Key facts

- **NCT ID:** NCT00450580
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2012-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450580, "HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00450580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*